TY - JOUR
T1 - Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C
AU - Dik, Kathelijne
AU - de Bruijne, Joep
AU - Takkenberg, R. Bart
AU - Roelofs, Joris J.
AU - Tempelmans, Marjan J.
AU - Dijkgraaf, Marcel G.W.
AU - Gelderblom, Huub C.
AU - Reesink, Henk W.
AU - Meijers, Joost C.M.
AU - Jansen, Peter L.
AU - Levi, Marcel
PY - 2012/7
Y1 - 2012/7
N2 - Aim: There is considerable variation in liver fibrosis stage and progression to cirrhosis among patients with chronic hepatitis B (CHB) or C (CHC). Coagulation pathway activity due to genetic variations could influence the rate of fibrosis. We investigated thrombotic risk factors and their association with the extent and progression of fibrosis in CHB or CHC patients. Methods: In total, 194 patients with CHB (n=88) or CHC (n=106) were included. Data on demographic and laboratory findings were collected. Liver biopsies were evaluated according to the Ishak classification system. Fibrosis progression rate (FPR), defined as ratio of fibrosis score to duration of infection, was determined for 131 patients. Prevalence of factor V Leiden, prothrombin G20210A, plasminogen activator inhibitor type-1 (PAI-1) 4G/5G and factor XIIIA Val34Leu mutations was evaluated. Results: Heterozygosity for factor V Leiden, prothrombin G20210A, PAI-1 4G/5G and factor XIIIA Val34Leu mutations was present in 3.1%, 2.1%, 49% and 28% of the patients, respectively. Factor XIII Val34Leu mutation was a risk for enhanced FPR (odds ratio 4.7; P=0.01). In patients with both factor XIII Val34Leu and PAI-1 4G/5G mutations the risk of an accelerated FPR was further increased (odds ratio 5.0; P=0.02). Mutations of the other thrombotic genes were not significantly associated with fibrosis stage and FPR. Conclusion: Our data show that factor XIII Val34Leu mutation alone or in combination with PAI-1 4G/5G mutation is a risk factor for an increased rate of liver fibrosis development in patients with CHB or CHC.
AB - Aim: There is considerable variation in liver fibrosis stage and progression to cirrhosis among patients with chronic hepatitis B (CHB) or C (CHC). Coagulation pathway activity due to genetic variations could influence the rate of fibrosis. We investigated thrombotic risk factors and their association with the extent and progression of fibrosis in CHB or CHC patients. Methods: In total, 194 patients with CHB (n=88) or CHC (n=106) were included. Data on demographic and laboratory findings were collected. Liver biopsies were evaluated according to the Ishak classification system. Fibrosis progression rate (FPR), defined as ratio of fibrosis score to duration of infection, was determined for 131 patients. Prevalence of factor V Leiden, prothrombin G20210A, plasminogen activator inhibitor type-1 (PAI-1) 4G/5G and factor XIIIA Val34Leu mutations was evaluated. Results: Heterozygosity for factor V Leiden, prothrombin G20210A, PAI-1 4G/5G and factor XIIIA Val34Leu mutations was present in 3.1%, 2.1%, 49% and 28% of the patients, respectively. Factor XIII Val34Leu mutation was a risk for enhanced FPR (odds ratio 4.7; P=0.01). In patients with both factor XIII Val34Leu and PAI-1 4G/5G mutations the risk of an accelerated FPR was further increased (odds ratio 5.0; P=0.02). Mutations of the other thrombotic genes were not significantly associated with fibrosis stage and FPR. Conclusion: Our data show that factor XIII Val34Leu mutation alone or in combination with PAI-1 4G/5G mutation is a risk factor for an increased rate of liver fibrosis development in patients with CHB or CHC.
KW - Coagulation
KW - factor V Leiden
KW - factor XIII Val34Leu mutation
KW - Fibrosis
KW - Hepatitis
KW - PAI-1 4G/5G mutation
UR - http://www.scopus.com/inward/record.url?scp=84862251086&partnerID=8YFLogxK
U2 - 10.1111/j.1872-034X.2011.00963.x
DO - 10.1111/j.1872-034X.2011.00963.x
M3 - Article
AN - SCOPUS:84862251086
SN - 1386-6346
VL - 42
SP - 668
EP - 676
JO - Hepatology Research
JF - Hepatology Research
IS - 7
ER -